What Is the Role of Maintenance Therapy in Cancer Care?

Beth Fand Incollingo @fandincollingo
Published: Wednesday, May 01, 2013
Dr. Dennis Citrin

Dennis Citrin, MD, PhD

Ten years ago, Dennis Citrin, MD, PhD watched as patients with metastatic non–small cell lung cancer died, despite treatment, 6 to 12 months after diagnosis.

Dr. Heather Wakelee

Heather Wakelee, MD

Without some of the newer, less-toxic cancer medications, MT wouldn’t be a workable strategy, particularly in NSCLC, noted Heather Wakelee, MD, assistant professor of Medicine in the Division of Oncology at Stanford University, in California.

Dr. Debu Tripathy

Debu Tripathy, MD

While the concept of MT remains under investigation in many types of solid tumors, the strategy has been adopted for eligible patients in some breast cancers—although doctors don’t always refer to it as MT, said Debu Tripathy, MD, co-leader of the Women’s Cancers Program and a professor of Medicine at the Norris Comprehensive Cancer Center at the University of Southern California in Los Angeles.

... to read the full story
To Read the Full Story

View Conference Coverage
OncLive SAP
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

Conference Coverage
OncLive TV
Peer Exchange
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.